Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 (‘Listing Regulations’), Sanofi India has informed that Annapurna Das (DIN: 08634664) Non-Executive Director has vide her letter dated 19th July 2023, resigned from the Board of Directors of the Company with effect from the close of business hours on 31st July 2023 to pursue other opportunities outside the company. Consequently, she shall also cease to be a Member of the Audit Committee of the Company. Further, the information required in terms of Regulation 30 read with Schedule III - Para A (7) of Part A of the SEBI Listing Regulations and SEBI Master Circular bearing Ref. No. SEBI/HO/CFD/ PoD2/CIR/P/2023/120 dated 11th July, 2023 is enclosed as ‘Annexure-I’ to this letter. The letter of resignation received from Annapurna Das is also enclosed.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |